The use of anti-angiogenic therapies has revolutionized the treatment of cancer. However,
some of these drugs are associated with cardiovascular damage. In the past, cardiotoxic risk was less
evident, but it is increasingly an issue, particularly with combination therapy and adjuvant therapy. An
early detection and personalized management is necessary to screen and treat an increase in blood pressure
or symptomatic left ventricular dysfunction. The interruption of treatment is recommended if cardiac
manifestations are uncontrolled, unless the expected benefit is greater than the risks. There is a need for cooperation
between these two areas and for the development of a novel discipline, which could be termed cardio-oncology or oncocardiology.
Keywords: Anti-angiogenic drugs, cardiovascular risk factors, heart failure, hypertension, left ventricular dysfunction, multitargeted
tyrosine kinase inhibitors.
Rights & PermissionsPrintExport